젠큐릭스
Financials
Valuation Metrics
젠큐릭스's Market Cap is ₩385B. At end of 2025 it was ₩363B. Ranked #1912 of 2,436 in KR market (top 78%), #1192 of 1,649 on KOSDAQ (top 72%), #79 of 96 in Health Care Equipment & Services (top 82%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 38.54B KRW | KR#1,912/2,436 Sec#79/96 |
| Revenue | 7.94B KRW | KR#2,308/2,436 Sec#84/96 |
| Net Income | -7.76B KRW | KR—/2,436 Sec—/96 |
| Total Assets | 31.09B KRW | KR#2,321/2,436 Sec#87/96 |
| Net Assets | 13.99B KRW | KR#2,335/2,436 Sec#93/96 |
| Employees | 68 | KR#1,884/2,436 Sec#77/96 |
| Value | ||
| P/B | 2.75x | KR#2,080/2,436 Sec#75/96 |
| P/S | 4.85x | KR#2,136/2,436 Sec#73/96 |
| FCF Yield | -16.44% | KR—/2,436 Sec—/96 |
| Profitability | ||
| ROE | -55.44% | KR#2,283/2,436 Sec#88/96 |
| ROA | -24.96% | KR#2,259/2,436 Sec#81/96 |
| Op. Margin | -75.62% | KR#2,285/2,436 Sec#81/96 |
| Revenue Growth | 23.13% | KR#588/2,436 Sec#28/96 |
| Earnings Growth | -233.60% | KR#1,524/2,436 Sec#51/96 |
| Financial Health | ||
| Debt Ratio | 122.16% | KR#702/2,436 Sec#33/96 |
| Total Debt | 10.43B KRW | KR#1,612/2,436 Sec#52/96 |
| FCF | -6.34B KRW | KR#1,568/2,436 Sec#53/96 |
| Cash | 169.9M KRW | KR#2,389/2,436 Sec#96/96 |
| Current Ratio | 0.56x | KR#2,221/2,436 Sec#90/96 |
| Performance | ||
| 1Y Return | 3.72% | KR#638/2,436 Sec#14/96 |
| 1M Return | -17.75% | KR#2,114/2,436 Sec#82/96 |
| From 52W High | -77.53% | KR#2,323/2,436 Sec#91/96 |
| 1Y MDD | -76.15% | KR#2,189/2,436 Sec#86/96 |
| Trading | ||
| Volume | 92,031 shares | KR#985/2,436 Sec#39/96 |
| Foreign Own. | 2.42% | KR—/2,436 Sec—/96 |
| Per Share | ||
| EPS | -435 KRW | KR—/2,436 Sec—/96 |
| BPS | 597 KRW | KR#2,374/2,436 Sec#93/96 |
Company Info
Genecurix, established in 2011 as a liquid biopsy-based molecular diagnostic testing technology enterprise, was listed on KOSDAQ in 2020. The company has developed innovative cancer diagnostic solutions, including Asia's first breast cancer prognosis diagnosis GeneSWell BCT, Droplex, and early diagnostic tests HEPA eDX and COLO eDX. Genecurix has acquired a stake in GinoBio to commercialize cfDNA and research CTC technology, fostering collaborations with leading companies in core technological fields. Genecurix is headquartered in Guro-gu, Seoul Metropolitan City.